Background
Alström syndrome (ALMS) is a rare autosomal recessive genetic disorder characterised by progressive endocrine disarray, sensorineural deficit, cardiac, renal, and hepatic abnormalities. Idiopathic infantile dilated cardiomyopathy (CMP) is common, presenting acutely in 45% of individuals and recurs or develops de novo in 65% of adolescents with high rates of morbidity and mortality. Myocardial fibrosis has been demonstrated at post-mortem and on MRI with patchy diffuse late gadolinium enhancement (LE) in an older cohort of ALMS patients. We hypothesise that subclinical diffuse fibrosis in young patients with ALMS precedes any change in conventional parameters of ventricular function or overt scarring on LE.
Methods
Thirteen patients (mean age 27 +/-11 years, 77% male, prevalence infantile CM 15%) from the National Specialist Commissioning Group for Alström Syndrome, Birmingham, UK and matched age and gender controls were prospectively assessed with 2D echocardiography and cardiac MRI (1.5T). Late gadolinium enhancement images were acquired 5-7 minutes after contrast. Myocardial extracellular volume (ECV) was assessed using T1-mapping pre and 15 minutes post gadolinium (0.1mmol/Kg) using a modified look-locker inversion recovery sequence (MOLLI) (Figures 1 &2) . Myocardial T1 was measured in the basal and mid septum avoiding areas of LE. 
Results

Septal myocardial ECV was increased in female ALMS
Conclusions
Patients with ALMS demonstrate a spectrum of myocardial fibrosis, which correlates with reduced longitudinal contractility before changes in conventional markers of LV structure and function. This precedes a clinically significant increase in BNP that appears with overt LE and suggests that increased ECV may be a target for early modification of pharmacological therapy. 
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